Background
tumor, Cancer
TUMOR, ADVANCED CANCER, CANCER
Edited by: Haijun Yu, Shanghai Institute of Materia Medica (CAS), ChinaReviewed by: AJ Robert McGray, University at Buffalo, United States; Julius Strauss, Center for Cancer Research, National Institutes of Health (NIH), United StatesThis article was submitted to Cancer Immunity and Immunotherapy, a section of the journal Frontiers in ImmunologyBromonitrozidine (RRx-001) is a minimally toxic, NLRP3 inhibitor that has been observed, in experimental systems, to also downregulate CD47, repolarize tumor associated macrophages (TAMs) and normalize aberrant tumor perfusion. This phase 1 pilot study was undertaken to determine the safety and feasibility of RRx-001 and nivolumab in patients with advanced cancer and no standard options.